Under the deal, Amsterdam Molecular Therapeutics (AMT) will receive the exclusive commercial rights to the final product. The combination of this gene with AMT’s proprietary adeno-associated virus gene therapy platform could potentially cure this seriously debilitating disease with a single administration of the product. Under the agreement AMT will sponsor research in hemophilia B at St Jude.
Ronald Lorijn, CEO of AMT, said: “Access to the Factor IX gene therapy program perfectly complements our gene therapy platform allowing us to develop an effective and long-lasting therapy for hemophilia B.”